Global Hereditary Angioedema Market Overview:
Global Hereditary Angioedema Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2026-2035, Considering the Base Year As 2025.
Global Hereditary Angioedema Market Report 2026 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2026-2035, with base year as 2025. This research study of Hereditary Angioedema involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Hereditary Angioedema Market:
The Hereditary Angioedema Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Hereditary Angioedema Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Hereditary Angioedema Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Hereditary Angioedema market has been segmented into:
C1 Esterase Inhibitors
Selective Bradykinin B2 Receptor Antagonists
Kallikrein Inhibitors
Other Drug Classes
By Application, Hereditary Angioedema market has been segmented into:
Subcutaneous Injections
Intravenous
Oral
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Hereditary Angioedema market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Hereditary Angioedema market.
Top Key Players Covered in Hereditary Angioedema market are:
BioCryst Pharmaceuticals Inc.
CSL Ltd.
iBio Inc.
Ionis Pharmaceuticals Inc.
Pharming Group NV
Shire PLC
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Hereditary Angioedema Market Type
4.1 Hereditary Angioedema Market Snapshot and Growth Engine
4.2 Hereditary Angioedema Market Overview
4.3 C1 Esterase Inhibitors
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.3.3 C1 Esterase Inhibitors: Geographic Segmentation Analysis
4.4 Selective Bradykinin B2 Receptor Antagonists
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.4.3 Selective Bradykinin B2 Receptor Antagonists: Geographic Segmentation Analysis
4.5 Kallikrein Inhibitors
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.5.3 Kallikrein Inhibitors: Geographic Segmentation Analysis
4.6 Other Drug Classes
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.6.3 Other Drug Classes: Geographic Segmentation Analysis
Chapter 5: Hereditary Angioedema Market Application
5.1 Hereditary Angioedema Market Snapshot and Growth Engine
5.2 Hereditary Angioedema Market Overview
5.3 Subcutaneous Injections
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.3.3 Subcutaneous Injections: Geographic Segmentation Analysis
5.4 Intravenous
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.4.3 Intravenous: Geographic Segmentation Analysis
5.5 Oral
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.5.3 Oral: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Hereditary Angioedema Market Share by Manufacturer (2025)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 BIOCRYST PHARMACEUTICALS
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 INC.; CSL LTD.; IBIO
6.4 INC.; IONIS PHARMACEUTICALS
6.5 INC.; PHARMING GROUP NV; SHIRE PLC
Chapter 7: Global Hereditary Angioedema Market By Region
7.1 Overview
7.2. North America Hereditary Angioedema Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 C1 Esterase Inhibitors
7.2.2.2 Selective Bradykinin B2 Receptor Antagonists
7.2.2.3 Kallikrein Inhibitors
7.2.2.4 Other Drug Classes
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Subcutaneous Injections
7.2.3.2 Intravenous
7.2.3.3 Oral
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Hereditary Angioedema Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 C1 Esterase Inhibitors
7.3.2.2 Selective Bradykinin B2 Receptor Antagonists
7.3.2.3 Kallikrein Inhibitors
7.3.2.4 Other Drug Classes
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Subcutaneous Injections
7.3.3.2 Intravenous
7.3.3.3 Oral
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Hereditary Angioedema Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 C1 Esterase Inhibitors
7.4.2.2 Selective Bradykinin B2 Receptor Antagonists
7.4.2.3 Kallikrein Inhibitors
7.4.2.4 Other Drug Classes
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Subcutaneous Injections
7.4.3.2 Intravenous
7.4.3.3 Oral
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Hereditary Angioedema Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 C1 Esterase Inhibitors
7.5.2.2 Selective Bradykinin B2 Receptor Antagonists
7.5.2.3 Kallikrein Inhibitors
7.5.2.4 Other Drug Classes
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Subcutaneous Injections
7.5.3.2 Intravenous
7.5.3.3 Oral
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Hereditary Angioedema Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 C1 Esterase Inhibitors
7.6.2.2 Selective Bradykinin B2 Receptor Antagonists
7.6.2.3 Kallikrein Inhibitors
7.6.2.4 Other Drug Classes
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Subcutaneous Injections
7.6.3.2 Intravenous
7.6.3.3 Oral
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Hereditary Angioedema Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 C1 Esterase Inhibitors
7.7.2.2 Selective Bradykinin B2 Receptor Antagonists
7.7.2.3 Kallikrein Inhibitors
7.7.2.4 Other Drug Classes
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Subcutaneous Injections
7.7.3.2 Intravenous
7.7.3.3 Oral
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Hereditary Angioedema Scope:
|
Report Data
|
Hereditary Angioedema Market
|
|
Hereditary Angioedema Market Size in 2025
|
USD XX million
|
|
Hereditary Angioedema CAGR 2025 - 2032
|
XX%
|
|
Hereditary Angioedema Base Year
|
2024
|
|
Hereditary Angioedema Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
BioCryst Pharmaceuticals Inc., CSL Ltd., iBio Inc., Ionis Pharmaceuticals Inc., Pharming Group NV, Shire PLC.
|
|
Key Segments
|
By Type
C1 Esterase Inhibitors
Selective Bradykinin B2 Receptor Antagonists
Kallikrein Inhibitors
Other Drug Classes
By Applications
Subcutaneous Injections
Intravenous
Oral
|
